Join to View Full Profile
250 25th Ave NSte 200Nashville, TN 37203
Phone+1 615-986-4366
Fax+1 615-320-1617
Dr. McKean is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2018
University of ColoradoResidency, Internal Medicine, 2012 - 2015
University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 2012
Certifications & Licensure
FL State Medical License 2020 - Present
TN State Medical License 2018 - 2027
KY State Medical License 2023 - 2026
NC State Medical License 2020 - 2022
AL State Medical License 2020 - 2020
TX State Medical License 2015 - 2020
CO State Medical License 2012 - 2015
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors.J Andrew Livingston, Jean-Yves Blay, Jonathan Trent, Claudia Valverde, Mark Agulnik
Clinical Cancer Research. 2025-02-17 - 1 citationsTIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa in patients with advanced solid tumors: a first-in-human, phase 1, dose-escalation trial.Aung Naing, Meredith McKean, Anthony Tolcher, Anja Victor, Ping Hu
Journal for Immunotherapy of Cancer. 2025-02-10 - Meeting Report From the 2023 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Philadelphia, PA, November 2023.Rino S Seedor, Andrew E Aplin, Corine Bertolotto, Richard D Carvajal, Nigel Deacon
Pigment Cell & Melanoma Research. 2025-01-01
Press Mentions
5 Skin Cancer-Care Tools You Should Look Out ForApril 24th, 2023- IDEAYA Biosciences (IDYA) Reports Positive Interim Phase 2 Data for Darovasertib and Crizotinib Combination and Successful FDA Type C MeetingApril 24th, 2023
- Tiragolumab plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-Positive Following ResectionSeptember 28th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
